Medtronic: A Long-Term Prospect (Perhaps)

Enter Medtronic. A titan, yes, but one with a touch more humility, or at least, a more reasonable valuation. A forward P/E of 16.3? A small mercy in these inflated times. A trifle below its five-year average, a detail that doesn’t shout from the rooftops, but whispers a quiet suggestion to those who listen.






